ZA936231B - Excitatory amino acid receptor antagonists - Google Patents

Excitatory amino acid receptor antagonists

Info

Publication number: ZA936231B
Authority: ZA; South Africa
Prior art keywords: alkyl; chr; hydrogen; chem; phenyl
Prior art date: 1992-09-03

Application number

ZA936231A

Other languages

English (en)

Inventor

Macklin Brian Arnold

Carl Franklin Betsch

Allen Robert Harkness

William Benry Walker Lunn

Paul Leslie Ornstein

Nancy Kay Augenstein

Marvin Martin Hansen

Bret Eugene Huff

Michael John Martinelli

Darryle Darwin Schoepp

Original Assignee

Lilly Co Eli

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1992-09-03

Filing date

1993-08-25

Publication date

1995-02-27

1993-08-25 Application filed by Lilly Co Eli filed Critical Lilly Co Eli

1995-02-27 Publication of ZA936231B publication Critical patent/ZA936231B/xx

Links

229940123511 Excitatory amino acid receptor antagonist Drugs 0.000 title abstract 2
229910052739 hydrogen Inorganic materials 0.000 abstract 5
239000001257 hydrogen Substances 0.000 abstract 5
125000004435 hydrogen atom Chemical class [H]* 0.000 abstract 5
125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract 4
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 4
125000002252 acyl group Chemical group 0.000 abstract 3
229910052717 sulfur Inorganic materials 0.000 abstract 3
125000000217 alkyl group Chemical group 0.000 abstract 2
125000003710 aryl alkyl group Chemical group 0.000 abstract 2
-1 hydroxy, amino, bromo, iodo Chemical group 0.000 abstract 2
229910052760 oxygen Inorganic materials 0.000 abstract 2
125000000008 (C1-C10) alkyl group Chemical group 0.000 abstract 1
125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 1
NENLYAQPNATJSU-UHFFFAOYSA-N 1,2,3,4,4a,5,6,7,8,8a-decahydroisoquinoline Chemical class C1NCCC2CCCCC21 NENLYAQPNATJSU-UHFFFAOYSA-N 0.000 abstract 1
208000012902 Nervous system disease Diseases 0.000 abstract 1
208000025966 Neurological disease Diseases 0.000 abstract 1
229910006069 SO3H Inorganic materials 0.000 abstract 1
125000004453 alkoxycarbonyl group Chemical group 0.000 abstract 1
230000015572 biosynthetic process Effects 0.000 abstract 1
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 abstract 1
125000001309 chloro group Chemical group Cl* 0.000 abstract 1
150000001875 compounds Chemical class 0.000 abstract 1
125000000753 cycloalkyl group Chemical group 0.000 abstract 1
239000000543 intermediate Substances 0.000 abstract 1
150000003839 salts Chemical class 0.000 abstract 1
125000000547 substituted alkyl group Chemical group 0.000 abstract 1
125000000020 sulfo group Chemical group O=S(=O)([*])O[H] 0.000 abstract 1
238000003786 synthesis reaction Methods 0.000 abstract 1
238000010189 synthetic method Methods 0.000 abstract 1
125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
- C07D217/26—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6524—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having four or more nitrogen atoms as the only ring hetero atoms

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
General Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Psychiatry (AREA)
Pain & Pain Management (AREA)
Addiction (AREA)
Molecular Biology (AREA)
Hospice & Palliative Care (AREA)
Psychology (AREA)
Urology & Nephrology (AREA)
Biochemistry (AREA)
Ophthalmology & Optometry (AREA)
Anesthesiology (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Otolaryngology (AREA)
Epidemiology (AREA)
Vascular Medicine (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Plural Heterocyclic Compounds (AREA)
Other In-Based Heterocyclic Compounds (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Peptides Or Proteins (AREA)

ZA936231A 1992-09-03 1993-08-25 Excitatory amino acid receptor antagonists ZA936231B (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US07/939,780 US5284957A (en)	1992-09-03	1992-09-03	Excitatory amino acid receptor antagonists

Publications (1)

Publication Number	Publication Date
ZA936231B true ZA936231B (en)	1995-02-27

Family

ID=25473721

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
ZA936231A ZA936231B (en)	1992-09-03	1993-08-25	Excitatory amino acid receptor antagonists

Country Status (27)

Country	Link
US (7)	US5284957A (xx)
EP (1)	EP0590789B9 (xx)
JP (1)	JP3601840B2 (xx)
KR (1)	KR100274367B1 (xx)
CN (1)	CN1043762C (xx)
AT (1)	ATE234287T1 (xx)
AU (1)	AU656482B2 (xx)
BR (1)	BR9303495A (xx)
CA (2)	CA2484248A1 (xx)
CZ (1)	CZ285049B6 (xx)
DE (1)	DE69332754T2 (xx)
DK (1)	DK0590789T3 (xx)
ES (1)	ES2194844T3 (xx)
FI (1)	FI933810A (xx)
HK (1)	HK1013989A1 (xx)
HU (2)	HU224015B1 (xx)
IL (1)	IL106809A (xx)
MX (1)	MX9305294A (xx)
MY (1)	MY131442A (xx)
NO (1)	NO304072B1 (xx)
NZ (1)	NZ248513A (xx)
PH (1)	PH31250A (xx)
PL (1)	PL173809B1 (xx)
PT (1)	PT590789E (xx)
RU (1)	RU2117661C1 (xx)
SG (1)	SG45319A1 (xx)
ZA (1)	ZA936231B (xx)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ES2087812B1 (es) *	1993-07-02	1997-03-16	Lilly Co Eli	Derivados de decahidroisoquinolina utiles como antagonistas de los receptrores de los aminoacidos excitadores.
US5580877A (en) *	1994-04-25	1996-12-03	Merck Sharp & Dohme Ltd.	Pyrazolo-quinoline derivatives for treating cerebral ischemia
US5446051A (en) *	1994-05-31	1995-08-29	Eli Lilly And Company	Aryl-spaced decahydroisoquinoline-3-carboxylic acids as excitatory amino acid receptor antagonists
US5723414A (en) *	1996-01-24	1998-03-03	Rohm And Haas Company	5-aryl-isoxazolinones and herbicidal use thereof
PT807633E (pt) *	1996-05-15	2003-02-28	Pfizer	Novas pirimidin-4-onas substituidas em 2,3, e fundidas com heteroarilo em (5,6)
SK284108B6 (sk)	1996-05-15	2004-09-08	Pfizer Inc.	2,3-Disubstituované 4(3H)-chinazolinóny, ich použitie a farmaceutické kompozície s ich obsahom
WO1998045270A1 (en)	1997-04-07	1998-10-15	Eli Lilly And Company	Pharmacological agents
US6627755B1 (en)	1997-06-09	2003-09-30	Pfizer Inc	Quinazolin-4-one AMPA antagonists
IL125950A0 (en) *	1997-09-05	1999-04-11	Pfizer Prod Inc	Methods of administering ampa receptor antagonists to treat dyskinesias associated with dopamine agonist therapy
US6323208B1 (en)	1997-09-05	2001-11-27	Pfizer Inc	Atropisomers of 2,3-disubstituted-(5.6)-heteroaryl fused-pyrimidin-4-ones
EP1066039A4 (en)	1998-03-02	2003-02-26	Cocensys Inc	SUBSTITUTED QUINAZOLINE AND THEIR ANALOGS AND USES
DE60032905T2 (de)	1999-07-06	2007-10-18	Eli Lilly And Co., Indianapolis	Selektive iglur5 rezeptorantagonisten zur behandlung der migräne
ATE240299T1 (de) *	1999-07-06	2003-05-15	Lilly Co Eli	Diester prodrugs von decahydroischinoline-3- carbonsäure
US6313159B1 (en)	1999-08-20	2001-11-06	Guilford Pharmaceuticals Inc.	Metabotropic glutamate receptor ligand derivatives as naaladase inhibitors
AU2574801A (en)	1999-12-22	2001-07-03	Eli Lilly And Company	Selective iGLUR5 receptor antagonists
AU2002227020A1 (en) *	2001-01-05	2002-07-16	Eli Lilly And Company	Pyrrolidinylmethyl- and piperidinyl substituted decahydroisoquinolines as excitatory amino acid receptor antagonists
US6924294B2 (en)	2001-01-05	2005-08-02	Eli Lilly And Company	Excitatory amino acid receptor antagonists
US7205313B2 (en) *	2001-01-05	2007-04-17	Eli Lilly And Company	Excitatory amino acid receptor antagonists
EP1351955A1 (en) *	2001-01-05	2003-10-15	Eli Lilly And Company	Excitatory amino acid receptor antagonists
PT1368032E (pt) *	2001-01-05	2008-09-04	Lilly Co Eli	Antagonistas de receptores dos aminoácidos excitadores
AU2002228736A1 (en) *	2001-01-05	2002-07-16	Eli Lilly And Company	Pyrrolidinylmethyl substituted decahydroisoquinolines as excitatory amino acid receptor antagonists
GB0106858D0 (en) *	2001-03-20	2001-05-09	Perkins Engines Co Ltd	An accessory drive for driving an engine accessory
GB0128996D0 (en) *	2001-12-04	2002-01-23	Novartis Ag	Organic compounds
US7091249B2 (en) *	2001-12-26	2006-08-15	University Of Iowa Research Foundation	Drugs for spinal anesthesia
AU2003219955A1 (en) *	2002-03-22	2003-10-13	Eli Lilly And Company	Isoquinoline-3-carboxylic acid derivatives as excitatory amino acid receptor antagonists
US20050176068A1 (en) *	2002-04-26	2005-08-11	Emmert-Buck Michael R.	Direct cell target analysis
KR100757787B1 (ko) *	2002-04-26	2007-09-11	일라이 릴리 앤드 캄파니	진통제로서의 데카히드로이소퀴놀린-3-카르복실산의 에스테르 유도체
GB0222056D0 (en) *	2002-09-23	2002-10-30	Novartis Ag	Process for the manufacture of organic compounds
US20040152694A1 (en) *	2003-02-04	2004-08-05	Istvan Kurucz	Methods and compositions for treating inflammatory disorders of the airways
US20060220794A1 (en) *	2005-04-04	2006-10-05	Jeffrey Zhu	Phase modulation for backscatter transponders
WO2007101116A2 (en) *	2006-02-24	2007-09-07	The Trustees Of Columbia University In The City Of New York	Glur2 receptor modulators
US20080108622A1 (en) *	2006-10-19	2008-05-08	Eisenach James C	Combination therapy for the treatment of pain
US20080108603A1 (en) *	2006-10-19	2008-05-08	Eisenach James C	Combination therapy for the treatment of pain
US20090270508A1 (en) *	2007-02-23	2009-10-29	James Eric Gouaux	GluR2 receptor modulators
EP2338492A1 (en)	2009-12-24	2011-06-29	Universidad del Pais Vasco	Methods and compositions for the treatment of alzheimer
CN101812031A (zh) *	2010-04-29	2010-08-25	南通市华峰化工有限责任公司	一种5-羟烷基四氮唑的高压生产方法
US9505728B2 (en)	2012-03-09	2016-11-29	Inception 2, Inc.	Triazolone compounds and uses thereof
CN104918922B (zh)	2012-12-20	2017-04-26	因森普深2公司	***酮化合物及其用途
TWI593692B (zh) *	2013-03-12	2017-08-01	美國禮來大藥廠	四氫吡咯并噻嗪化合物
CN105579440A (zh)	2013-09-06	2016-05-11	因森普深2公司	***酮化合物及其应用
CA3066711A1 (en)	2017-07-31	2019-02-07	Novartis Ag	Use of mavoglurant in the reduction of *e use or in preventing relapse into *e use
MX2022016223A (es) *	2020-07-02	2023-02-23	Sea Pharmaceuticals Llc	Composiciones farmaceuticas de acido 6-(2-(2h-tetrazol-5-il)etil)- 6-fluorodecahidroisoquinolina-3-carboxilico y derivados de ester del mismo.

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DK704488D0 (da) *	1988-12-19	1988-12-19	Novo Industri As	Nye n-substituerede azaheterocykliske carboxylsyrer
US4897490A (en) *	1987-02-25	1990-01-30	Bristol-Meyers Company	Antihypercholesterolemic tetrazole compounds
US4824959A (en) *	1988-02-18	1989-04-25	Bristol-Myers Company	Intermediates for antihypercholesterolemic tetrazole compounds
US4902695A (en) *	1989-02-13	1990-02-20	Eli Lilly And Company	Excitatory amino acid receptor antagonists
US5192751A (en) *	1992-07-24	1993-03-09	Eli Lilly And Company	Use of competitive NMDA receptor antagonists in the treatment of urinary incontinence

1992
- 1992-09-03 US US07/939,780 patent/US5284957A/en not_active Expired - Lifetime
1993
- 1993-08-25 ES ES93306745T patent/ES2194844T3/es not_active Expired - Lifetime
- 1993-08-25 ZA ZA936231A patent/ZA936231B/xx unknown
- 1993-08-25 SG SG1996003438A patent/SG45319A1/en unknown
- 1993-08-25 DK DK93306745T patent/DK0590789T3/da active
- 1993-08-25 AT AT93306745T patent/ATE234287T1/de active
- 1993-08-25 DE DE69332754T patent/DE69332754T2/de not_active Expired - Lifetime
- 1993-08-25 CZ CZ931745A patent/CZ285049B6/cs not_active IP Right Cessation
- 1993-08-25 EP EP93306745A patent/EP0590789B9/en not_active Expired - Lifetime
- 1993-08-25 US US08/111,747 patent/US5399696A/en not_active Expired - Lifetime
- 1993-08-25 PT PT93306745T patent/PT590789E/pt unknown
- 1993-08-26 BR BR9303495A patent/BR9303495A/pt not_active Application Discontinuation
- 1993-08-26 CA CA002484248A patent/CA2484248A1/en not_active Abandoned
- 1993-08-26 IL IL10680993A patent/IL106809A/en not_active IP Right Cessation
- 1993-08-26 CA CA002104909A patent/CA2104909C/en not_active Expired - Lifetime
- 1993-08-27 NZ NZ248513A patent/NZ248513A/en unknown
- 1993-08-27 PH PH46762A patent/PH31250A/en unknown
- 1993-08-30 HU HU9302453A patent/HU224015B1/hu active IP Right Grant
- 1993-08-31 FI FI933810A patent/FI933810A/fi unknown
- 1993-08-31 AU AU46003/93A patent/AU656482B2/en not_active Expired
- 1993-08-31 RU RU93049265A patent/RU2117661C1/ru active
- 1993-08-31 NO NO933100A patent/NO304072B1/no not_active IP Right Cessation
- 1993-08-31 MX MX9305294A patent/MX9305294A/es unknown
- 1993-09-01 KR KR1019930017398A patent/KR100274367B1/ko not_active IP Right Cessation
- 1993-09-01 MY MYPI93001753A patent/MY131442A/en unknown
- 1993-09-01 JP JP21744193A patent/JP3601840B2/ja not_active Expired - Lifetime
- 1993-09-01 CN CN93117627A patent/CN1043762C/zh not_active Expired - Lifetime
- 1993-09-01 PL PL93300250A patent/PL173809B1/pl unknown
1994
- 1994-11-21 US US08/343,079 patent/US5637712A/en not_active Expired - Lifetime
1995
- 1995-06-01 US US08/457,766 patent/US5675008A/en not_active Expired - Lifetime
- 1995-06-01 US US08/456,439 patent/US5670516A/en not_active Expired - Lifetime
- 1995-06-01 US US08/457,556 patent/US5606062A/en not_active Expired - Lifetime
- 1995-06-01 US US08/456,577 patent/US5648492A/en not_active Expired - Lifetime
- 1995-06-22 HU HU95P/P00401P patent/HU211992A9/hu unknown
1998
- 1998-12-23 HK HK98115176A patent/HK1013989A1/xx not_active IP Right Cessation

Also Published As

Publication number	Publication date
AU656482B2 (en)	1995-02-02
ES2194844T3 (es)	2003-12-01
DE69332754T2 (de)	2004-06-17
JPH06199802A (ja)	1994-07-19
CA2104909C (en)	2005-01-11
US5284957A (en)	1994-02-08
MX9305294A (es)	1994-06-30
NO933100L (no)	1994-03-04
PL173809B1 (pl)	1998-05-29
HU211992A9 (en)	1996-01-29
CA2484248A1 (en)	1994-03-04
NO304072B1 (no)	1998-10-19
KR100274367B1 (ko)	2000-12-15
HU224015B1 (hu)	2005-04-28
CA2104909A1 (en)	1994-03-04
HK1013989A1 (en)	1999-09-17
HUT65228A (en)	1994-05-02
US5606062A (en)	1997-02-25
JP3601840B2 (ja)	2004-12-15
RU2117661C1 (ru)	1998-08-20
EP0590789A1 (en)	1994-04-06
SG45319A1 (en)	1998-01-16
US5670516A (en)	1997-09-23
US5399696A (en)	1995-03-21
NO933100D0 (no)	1993-08-31
CZ285049B6 (cs)	1999-05-12
ATE234287T1 (de)	2003-03-15
IL106809A (en)	1999-03-12
US5637712A (en)	1997-06-10
KR940007021A (ko)	1994-04-26
CN1043762C (zh)	1999-06-23
PT590789E (pt)	2003-07-31
MY131442A (en)	2007-08-30
US5675008A (en)	1997-10-07
AU4600393A (en)	1994-03-10
EP0590789B9 (en)	2004-02-04
EP0590789B1 (en)	2003-03-12
HU9302453D0 (en)	1993-11-29
FI933810A0 (fi)	1993-08-31
CN1091129A (zh)	1994-08-24
DK0590789T3 (da)	2004-03-22
BR9303495A (pt)	1994-03-22
DE69332754D1 (de)	2003-04-17
US5648492A (en)	1997-07-15
PH31250A (en)	1998-06-18
FI933810A (fi)	1994-03-04
NZ248513A (en)	1996-02-27
CZ174593A3 (en)	1994-03-16

Publication	Publication Date	Title
SG45319A1 (en)	1998-01-16	Excitatory amino acid receptor antagonists
MX19368A (es)	1993-09-01	Procedimiento para la preparacion de derivados heterociclicos que contienen nitrogeno benzofusionado y compuesto obtenido.
ES548418A0 (es)	1987-01-16	Un procedimiento para preparar un compuesto de piperazina
GB8719102D0 (en)	1987-09-16	Therapeutic agents
HUT57773A (en)	1991-12-30	Process for produicng n-(aminocarbonyl)-carbamates related to physostigmine, as well as pharmaceutical compositions comprising such compounds
PL339143A1 (en)	2000-12-04	Tetrahydro-gamma-carbolynes
ATE141606T1 (de)	1996-09-15	Cephemverbindungen und verfahren zu ihrer herstellung
DE3783579D1 (de)	1993-02-25	Derivate des alpha-anp und ihre herstellung.
DK0648762T3 (da)	2001-07-30	Bicykliske forbindelser som excitatoriske aminosyrereceptorantagonister
DK0541263T3 (da)	1995-04-18	5-Piperazinylalkyl-1,5-benzothiazepinoner, der er nyttige som calciumantagonister
HU895648D0 (en)	1990-01-28	Process for the preparation of n,n-disubstituted diaryl-alkancarboxylic acid amide derivatives and pharmaceutical compositions containing such compounds
HUT57211A (en)	1991-11-28	Process for producing pyrrolo-pyrimidine derivatives, pharmaceutically acceptable salts thereof and pahrmaceutical compositions containing them as active components
HUT45059A (en)	1988-05-30	Process for producing abeoergoline derivatives
ATE113950T1 (de)	1994-11-15	4,5,6,11-tetrahydrobenzo(6,7>-cycloocta(1,2- b>thiophen-6,11-imine und 6,11-dihydrobenzo(6,7>- cycloocta(1,2-b>thiophen-6,11-imine.
DE69708640T2 (de)	2002-08-08	Pyridoncarbonsäure-derivate und zwischenverbindungen für deren herstellung
ATE108444T1 (de)	1994-07-15	3-isoxazolonderivate, ihre herstellung und ihre anwendung in der therapeutik.